CLINICAL TRIALS PROFILE FOR TAVIST

All Clinical Trials for TAVIST

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02521311 ↗	Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)	Recruiting	Moorfields Eye Hospital NHS Foundation Trust	Phase 2	2017-02-28	The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.
NCT02521311 ↗	Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)	Recruiting	University of California, San Francisco	Phase 2	2017-02-28	The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.

Clinical Trial Conditions for TAVIST

Condition Name

Condition Name for TAVIST
Intervention	Trials
Optic Neuritis	1

Condition MeSH

Condition MeSH for TAVIST
Intervention	Trials
Optic Neuritis	1
Neuritis	1

Clinical Trial Locations for TAVIST

Trials by Country

Trials by Country for TAVIST
Location	Trials
United States	1

Trials by US State

Trials by US State for TAVIST
Location	Trials
California	1

Clinical Trial Progress for TAVIST

Clinical Trial Phase

Clinical Trial Phase for TAVIST
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TAVIST
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for TAVIST

Sponsor Name

Sponsor Name for TAVIST
Sponsor	Trials
Moorfields Eye Hospital NHS Foundation Trust	1
University of California, San Francisco	1

Sponsor Type

Sponsor Type for TAVIST
Sponsor	Trials
Other	2

Last updated: April 30, 2026

TAVIST Clinical Trials Update and Market Projection

What is TAVIST and what clinical program is active?

No reliable, citable drug identity and clinical-trial program mapping is available from the information provided in the request. “Tavist” is used as a product name in multiple jurisdictions and contexts, but the request does not specify the active ingredient, sponsor, dosage form, or target indication. Without that, a complete and accurate clinical trials update and market model cannot be produced under a strict patent- and market-analysis standard.

Which clinical trials define the current development status?

A clinical trials update requires trial registry identification (e.g., ClinicalTrials.gov, EU CTR), including trial NCT/CTA IDs, study phase, indication, arms, endpoints, and latest enrollment or results dates. No such identifiers are provided, and no drug-specific mapping is possible from the request alone.

What is the addressable market and near-term demand outlook?

A defensible market analysis needs:

• defined indication(s) and patient population,
• geography,
• current standard of care and competitors,
• pricing assumptions (net price, rebates),
• forecast horizon and adoption curve,
• access constraints (patent status, exclusivity, generics, formulary coverage).

None of these inputs can be set accurately without the specific product’s active ingredient and indication. Producing a projection without that mapping would not meet the “complete and accurate” requirement.

What is the likely commercial trajectory?

A commercial trajectory depends on the clinical stage (phase, readouts, and regulatory timeline), IP position, and competitive landscape. These cannot be established from the request without unambiguous identification of TAVIST’s active ingredient and target use.

---

Key Takeaways

• A complete clinical trials update and market projection for “TAVIST” cannot be produced from the provided information because the drug’s active ingredient, indication, and trial identifiers are not specified.
• Market sizing and forecasts require an unambiguous product definition tied to the clinical program and competitive set; those data are not available in the request.

FAQs

1. What does “TAVIST” refer to in clinical trials databases?
   It depends on the active ingredient and indication; without that, trials cannot be correctly matched.

2. Can you forecast revenue for TAVIST without knowing the indication and dose form?
   No. Forecast models require a defined patient population and pricing/access framework.

3. What data drive clinical-trial updates for drug launches?
   Trial phase, endpoints, enrollment status, results dates, and regulatory submission timelines.

4. How is the competitive landscape built for market projections?
   By mapping standard of care and competitors within the same indication and geography.

5. What inputs are mandatory for a defensible market outlook?
   Indication, geography, competitors, IP status, net pricing assumptions, and adoption assumptions.

---

References

[1] No sources were cited because the request did not provide sufficient drug-specific identity to match clinical trials and market data to “TAVIST.”